Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Dora Tihanyi"'
Autor:
Istvan Petak, Maud Kamal, Anna Dirner, Ivan Bieche, Robert Doczi, Odette Mariani, Peter Filotas, Anne Salomon, Barbara Vodicska, Vincent Servois, Edit Varkondi, David Gentien, Dora Tihanyi, Patricia Tresca, Dora Lakatos, Nicolas Servant, Julia Deri, Pauline du Rusquec, Csilla Hegedus, Diana Bello Roufai, Richard Schwab, Celia Dupain, Istvan T. Valyi-Nagy, Christophe Le Tourneau
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-11 (2021)
Abstract Precision oncology is currently based on pairing molecularly targeted agents (MTA) to predefined single driver genes or biomarkers. Each tumor harbors a combination of a large number of potential genetic alterations of multiple driver genes
Externí odkaz:
https://doaj.org/article/25368c6568c249e3961734d462c71641
Autor:
Richard Schwab, Dóra Kormos, Edit Várkondi, Zsolt Pápai-Székely, Magdolna Horváth, Róbert Dóczi, Csilla Hegedüs, István Peták, Zsuzsanna Póka-Farkas, Dora Tihanyi, István Takacs, László Urbán, Barbara Vodicska, István Vályi-Nagy
Publikováno v:
Clinical Lung Cancer. 22:e112-e115
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b221eb75de5cf9dc4e7dfd7dce5f4f8
https://doi.org/10.1016/j.cllc.2020.09.005
https://doi.org/10.1016/j.cllc.2020.09.005
Autor:
Odette Mariani, Edit Várkondi, Ivan Bièche, István Peták, Csilla Hegedüs, David Gentien, Diana Bello Roufai, Anne Vincent Salomon, Julia Deri, Christophe Le Tourneau, Pauline du Rusquec, Nicolas Servant, Barbara Vodicska, Richard Schwab, Vincent Servois, Dóra Lakatos, Dora Tihanyi, Róbert Dóczi, Anna Dirner, Celia Dupain, P. Filotas, Maud Kamal, István Vályi-Nagy, P. Tresca
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-11 (2021)
NPJ Precision Oncology
NPJ Precision Oncology
Precision oncology is currently based on pairing molecularly targeted agents (MTA) to predefined single driver genes or biomarkers. Each tumor harbors a combination of a large number of potential genetic alterations of multiple driver genes in a comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4f791853a330d4ab5b91c92a495c54
https://doi.org/10.1038/s41698-021-00191-2
https://doi.org/10.1038/s41698-021-00191-2
Autor:
Istvan Petak, Barbara Vodicska, Eniko Kispeter, Robert Doczi, Dora Tihanyi, Dora Lakatos, Anna Dirner, Matyas Vidermann, Reka Szalkai-Denes, Dora Mathiasz, Richard Schwab, Istvan T. Valyi-Nagy
Publikováno v:
Journal of Clinical Oncology. 40:e13618-e13618
e13618 Background: Comprehensive molecular profiling is readily available for clinical practice. An extensive amount of published evidence provides information about the potential functional relevance of many driver genes and genetic alterations. But
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b29450c6fd973388a97690b51e5a321
https://doi.org/10.1200/jco.2022.40.16_suppl.e13618
https://doi.org/10.1200/jco.2022.40.16_suppl.e13618
Autor:
Istvan Petak, Barbara Vodicska, Eniko Kispeter, Robert Doczi, Dora Tihanyi, Dora Lakatos, Anna Dirner, Matyas Vidermann, Reka Szalkai-Denes, Julia Deri, Maud Kamal, Richard Schwab, Christophe Le Tourneau
Publikováno v:
Journal of Clinical Oncology. 40:e13616-e13616
e13616 Background: Several molecularly targeted agents (MTA) are registered in the same indication, even in the same line, to treat gastrointestinal (GI) cancers. Comprehensive molecular profiling is readily available for many patients, but only a fe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::574081e9971c21554b949bb5c179deeb
https://doi.org/10.1200/jco.2022.40.16_suppl.e13616
https://doi.org/10.1200/jco.2022.40.16_suppl.e13616
Autor:
László Urbán, Anna Dirner, Barbara Vodicska, Dóra Lakatos, László Tóth, Edit Várkondi, István Vályi-Nagy, István Takacs, Dora Tihanyi, István Peták, Róbert Dóczi, Dóra Kormos
Publikováno v:
Journal of Personalized Medicine, Vol 10, Iss 107, p 107 (2020)
Journal of Personalized Medicine
Journal of Personalized Medicine
Background: The anaplastic lymphoma kinase (ALK) gene fusion rearrangement is a potent oncogene, accounting for 2–7% of lung adenocarcinomas, with higher incidence (17–20%) in non-smokers. ALK-positive tumors are sensitive to ALK tyrosine kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e40e2d7e4a96b97b2f49bb0a43f339bf
https://www.mdpi.com/2075-4426/10/3/107
https://www.mdpi.com/2075-4426/10/3/107
Autor:
Julia Deri, Róbert Dóczi, Barbara Vodicska, Dora Tihanyi, István Peták, István Vályi-Nagy, Judita Szkukalek, Anna Dirner, Dóra Lakatos, Ákos Boldizsár, Zsuzsanna Nagy, Edit Várkondi, Ágnes Varga, Richard Schwab, Gábor Pajkos, Dorottya Valtinyi
Publikováno v:
Diagnostics
Diagnostics, Vol 11, Iss 1850, p 1850 (2021)
Diagnostics, Vol 11, Iss 1850, p 1850 (2021)
Background: We present the case of a 50-year-old female whose metastatic pancreatic neuroendocrine tumor (pNET) diagnosis was delayed by the COVID-19 pandemic. The patient was in critical condition at the time of diagnosis due to the extensive tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44402a14e9c8830b5b26976d90f2b9b1
https://doi.org/10.3390/diagnostics11101850
https://doi.org/10.3390/diagnostics11101850
Autor:
B. Vodicska, R. Simon, P. Filotas, Peter Hauser, Miklós Garami, E. Várkondi, István Szegedi, J. Deri, C. Hegedues, György Péter, István Peták, Csongor Kiss, Dora Tihanyi, Krisztina Mita Gabor, Katalin Bartyik
Publikováno v:
Annals of Oncology. 31:S1103
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e1187181f949b3aab6984108d91a97a
https://doi.org/10.1016/j.annonc.2020.08.1349
https://doi.org/10.1016/j.annonc.2020.08.1349
Autor:
Nicolas Servant, Richard Schwab, Edit Várkondi, Anna Dirner, Christophe Le Tourneau, Róbert Dóczi, Barbara Vodicska, Csilla Hegedűs, Maud Kamal, István Vályi-Nagy, Celia Dupain, István Peták, Dora Tihanyi, P. Filotas
Publikováno v:
Journal of Clinical Oncology. 38:3642-3642
3642 Background: Precision oncology requires the identification of individual molecular pathomechanisms to find optimal personalized treatment strategies for every cancer patient. Incorporation of complex molecular information into routine clinical p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90b5a4f1fd0655f9fb19cff0626518ed
https://doi.org/10.1200/jco.2020.38.15_suppl.3642
https://doi.org/10.1200/jco.2020.38.15_suppl.3642
Autor:
Róbert Dóczi, Attila Mate, István Peták, M Bacskai, István Vályi-Nagy, Csilla Hegedüs, P. Filotas, Dora Tihanyi, Richard Schwab
Publikováno v:
Journal of Global Oncology. 5:35-35
35 Background: Most tumours harbor multiple driver genetic alterations and many driver alterations are linked to multiple targeted therapies with various level of evidence. In addition, a specific treatment can be linked to multiple genetic alteratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c41e180935b66705a88eaf0bf69bdcba
https://doi.org/10.1200/jgo.2019.5.suppl.35
https://doi.org/10.1200/jgo.2019.5.suppl.35